[go: up one dir, main page]

SG146657A1 - Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists - Google Patents

Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Info

Publication number
SG146657A1
SG146657A1 SG200806914-8A SG2008069148A SG146657A1 SG 146657 A1 SG146657 A1 SG 146657A1 SG 2008069148 A SG2008069148 A SG 2008069148A SG 146657 A1 SG146657 A1 SG 146657A1
Authority
SG
Singapore
Prior art keywords
additional
compounds
receptor antagonists
metabotropic glutamate
glutamate receptor
Prior art date
Application number
SG200806914-8A
Other languages
English (en)
Inventor
Louise Edwards
Methvin Isaac
Martin Johansson
Annika Kers
Johan Malmberg
Donald Mcleod
Alexander Minidis
Karin Staaf
Abdelmalik Slassi
Tomislav Stefanac
Thomas Stormann
David Wensbo
Xin Tao
Jalaj Arora
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG146657A1 publication Critical patent/SG146657A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG200806914-8A 2004-02-18 2005-02-15 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists SG146657A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60896004P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
SG146657A1 true SG146657A1 (en) 2008-10-30

Family

ID=35447957

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200806914-8A SG146657A1 (en) 2004-02-18 2005-02-15 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Country Status (26)

Country Link
US (6) US7585881B2 (fr)
EP (2) EP2311830A1 (fr)
JP (1) JP4912157B2 (fr)
CN (2) CN1984907A (fr)
AT (1) ATE483706T1 (fr)
AU (1) AU2005270208A1 (fr)
BR (1) BRPI0507497A (fr)
CA (1) CA2555566A1 (fr)
CY (1) CY1110965T1 (fr)
DE (1) DE602005023963D1 (fr)
DK (1) DK1723144T3 (fr)
ES (1) ES2352110T3 (fr)
HR (1) HRP20100654T1 (fr)
IL (1) IL177394A0 (fr)
NO (1) NO20063599L (fr)
NZ (1) NZ548954A (fr)
PL (1) PL1723144T3 (fr)
PT (1) PT1723144E (fr)
RS (1) RS51516B (fr)
RU (1) RU2370495C2 (fr)
SG (1) SG146657A1 (fr)
SI (1) SI1723144T1 (fr)
UA (1) UA84318C2 (fr)
UY (1) UY28766A1 (fr)
WO (1) WO2006014185A1 (fr)
ZA (1) ZA200606551B (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1894241A (zh) * 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CA2563615A1 (fr) * 2004-04-20 2005-11-03 Merck & Co., Inc. Derives de phenyle 1,3,5-substitues utiles comme inhibiteurs de la beta-secretase pour le traitement de la maladie d'alzheimer
WO2006080533A1 (fr) * 2005-01-31 2006-08-03 Mochida Pharmaceutical Co., Ltd. Dérivé de 3-amino-1,2,4-triazole
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I
TW200808800A (en) * 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
TW200811179A (en) * 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators VI
US7935715B2 (en) * 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
TW200821305A (en) * 2006-10-05 2008-05-16 Astrazeneca Ab MGluR5 modulators
WO2008145616A1 (fr) * 2007-05-25 2008-12-04 Abbott Gmbh & Co. Kg Composés hétérocycliques comme modulateurs positifs du récepteur métabotropique du glutamate 2 (récepteur mglu2)
WO2009010455A2 (fr) 2007-07-13 2009-01-22 Addex Pharma S.A. Nouveaux dérivés hétéroaromatiques et leur utilisation en tant que modulateurs allostériques positifs des récepteurs métabotropiques du glutamate
JP2011500673A (ja) * 2007-10-19 2011-01-06 アストラゼネカ・アクチエボラーグ 代謝調節型グルタミン酸受容体（ｍｇｌｕｒｓ）の調節因子としてのテトラゾール誘導体
WO2009054785A1 (fr) * 2007-10-26 2009-04-30 Astrazeneca Ab Dérivés d'éther de 1,2,4-triazole comme modulateurs de mglur5
WO2009054786A1 (fr) * 2007-10-26 2009-04-30 Astrazeneca Ab Dérivés de n-oxydes d'aryle 1,2,4-triazole utilisés en tant que modulateurs de mglur5
WO2009061652A1 (fr) * 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Composés modulant le récepteur cb2
AU2009223833A1 (en) * 2008-03-03 2009-09-17 Stiefel Laboratories, Inc. Processes for preparing enantiomerically pure diol and dioxolane compounds
PL2291080T3 (pl) * 2008-05-14 2015-12-31 Scripps Research Inst Nowe modulatory receptorów sfingozyno-1-fosforanu
WO2010005782A1 (fr) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Composés sulfones qui modulent le récepteur cb2
MX2011001549A (es) * 2008-08-12 2011-03-15 Astrazeneca Ab Forma cristalina de 4-(5-{(1r)-1-[5-(3-clorofenil)isoxazol-3-il]et oxi}-4-metil-4h-1,2,4-triazol-3-il)piridina.
CN102176910A (zh) * 2008-08-12 2011-09-07 阿斯利康(瑞典)有限公司 4-(5-{(1r)-1-[5-(3-氯苯基)异噁唑-3-基]乙氧基}-4-甲基-4h-1,2,4-三唑-3-基)吡啶的新晶体形式
KR20110063438A (ko) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
WO2010071559A1 (fr) * 2008-12-18 2010-06-24 Astrazeneca Ab Nouveau procédé 447
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010096371A2 (fr) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Composés hétérocycliques qui modulent le récepteur cb2
US20120029190A1 (en) * 2009-04-03 2012-02-02 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US20100273805A1 (en) * 2009-04-23 2010-10-28 Astrazeneca Ab Sulphide bridged derivatives as modulators of mglur5 733
US8883827B2 (en) 2009-06-05 2014-11-11 Oslo University Hospital Hf Azole derivatives as WTN pathway inhibitors
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (fr) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Dérivés d'azétidine 2-carboxamide qui modulent le récepteur cb2
US8383651B2 (en) * 2009-09-22 2013-02-26 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
PT2498611T (pt) 2009-11-13 2018-04-13 Celgene Int Ii Sarl Moduladores de recetor de esfingosina 1 fosfato e métodos de síntese quiral
DK2498609T3 (en) * 2009-11-13 2018-06-18 Celgene Int Ii Sarl SELECTIVE HETEROCYCLIC SPHINGOSIN-1 PHOSPHATRECEPTOR MODULATORS
CA2780772C (fr) 2009-11-13 2018-01-16 Receptos, Inc. Modulateurs selectifs du recepteur de sphingosine-1-phosphate et procedes de synthese chirale
CN101712641B (zh) * 2009-12-29 2013-05-08 江苏工业学院 一种甲硫基苯甲酸的制备方法
WO2011082010A1 (fr) 2009-12-29 2011-07-07 Eli Lilly And Company Composés de tétrahydrotriazolopyridine en tant que potentialisateurs sélectifs de récepteur mglu5 utiles pour le traitement de la schizophrénie
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
WO2011092293A2 (fr) 2010-02-01 2011-08-04 Novartis Ag Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf
US8835444B2 (en) 2010-02-02 2014-09-16 Novartis Ag Cyclohexyl amide derivatives as CRF receptor antagonists
WO2011109324A1 (fr) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Composés tétrazoles qui modulent sélectivement le récepteur cb2
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133920A1 (fr) 2010-04-23 2011-10-27 Cytokinetics, Inc. Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
WO2012058128A2 (fr) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Modulateurs caprolactames des récepteurs mglur5
CN103429583A (zh) 2010-12-08 2013-12-04 奥斯陆大学医院公司 作为wnt信号通路抑制剂的三唑衍生物
DE102010063974B4 (de) * 2010-12-22 2021-10-07 Thomas Rühl Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung
MX2013010698A (es) 2011-03-18 2014-02-17 Novartis Ag Combinaciones de activadores del receptor de acetil-colina nicotinico alfa-7 y antagonistas del receptor de glutamato metabotropico 5 (mglur5) para usarse en la discinesia inducida por dopamina en la enfermedad de parkinson.
US8759380B2 (en) * 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
ES2758841T3 (es) 2011-05-13 2020-05-06 Celgene Int Ii Sarl Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
DK3363790T3 (da) 2013-09-06 2020-04-27 Aurigene Discovery Tech Ltd 1,2,4-oxadiazolderivater som immunmodulatorer
DK3265446T3 (da) * 2015-03-05 2019-10-28 Bayer Cropscience Ag Fremgangsmåde til fremstilling af substituerede phenylisoxazolinderivater
SG11201706902SA (en) * 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
CU24509B1 (es) 2015-03-10 2021-05-12 Aurigene Discovery Tech Ltd Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
SI3730487T1 (sl) 2016-06-13 2022-08-31 Gilead Sciences, Inc. Azetidinski derivati kot modulatorji FXR (NR1H4)
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
WO2019061324A1 (fr) 2017-09-29 2019-04-04 Curis Inc. Formes cristallines d'immunomodulateurs
ES2950757T3 (es) 2017-10-06 2023-10-13 Forma Therapeutics Inc Inhibición de la peptidasa específica de la ubiquitina 30
KR20240151258A (ko) 2017-10-11 2024-10-17 오리진 온콜로지 리미티드 3-치환된 1,2,4-옥사다이아졸의 결정질 형태
EA202090746A1 (ru) 2017-11-03 2020-08-17 Ориджен Дискавери Текнолоджис Лимитед Двойные ингибиторы путей tim-3 и pd-1
CN111386128A (zh) 2017-11-06 2020-07-07 奥瑞基尼探索技术有限公司 用于免疫调节的联合疗法
JP7153734B2 (ja) * 2017-11-16 2022-10-14 モンドレックス・インコーポレーテッド モノアミジン及びジアミジンのエンド－エキソヌクレアーゼ阻害剤とエンド－エキソヌクレアーゼ活性を阻害する方法
BR112020021921A2 (pt) 2018-05-17 2021-01-26 Forma Therapeutics, Inc. compostos bicíclicos fundidos úteis como inibidores de peptidase 30 específica de ubiquitina
LT3860989T (lt) 2018-10-05 2023-06-12 Forma Therapeutics, Inc. Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai
US11225473B2 (en) 2019-01-15 2022-01-18 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
EP3927683A1 (fr) 2019-02-19 2021-12-29 Gilead Sciences, Inc. Formes solides d'agonistes de fxr
BR112021022067A2 (pt) * 2019-05-03 2022-05-17 Praxis Prec Medicines Inc Inibidores de kcnt1 e métodos de uso
KR20220097405A (ko) * 2019-11-05 2022-07-07 클라에스 툴린 포유동물에서의 혹사의 예방 및/또는 치료에 사용하기 위한 4-[5-[(rac)-1-[5-(3-클로로페닐)-3-이속사졸일]에톡시]-4-메틸-4H-1,2,4-트리아졸-3-일]피리딘
UA128949C2 (uk) 2020-01-07 2024-12-04 Дісарм Серап'Ютікс, Інк. Інгібітори sarm1
TWI786777B (zh) 2020-08-24 2022-12-11 美商達薩瑪治療公司 Sarm1之抑制劑
WO2022231872A1 (fr) * 2021-04-29 2022-11-03 Praxis Precision Medicines, Inc. Inhibiteurs de kcnt1 et méthodes d'utilisation
CN119173506A (zh) 2022-05-19 2024-12-20 阿斯利康(瑞典)有限公司 用于治疗肝病的酰胺杂芳香族化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4538833A (en) * 1983-12-08 1985-09-03 P I E International Inc. Publication
US5403138A (en) * 1991-10-09 1995-04-04 Fuji Photo Film Co., Ltd. Booklet album including a double-sided photograph and a method of making the same
US5332265A (en) * 1993-01-22 1994-07-26 Minnesota Mining And Manufacturing Company Advertising assembly
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
ATE307129T1 (de) 1999-08-19 2005-11-15 Nps Pharma Inc Heteropolycyclische verbindungen und ihre verwendung als antagonisten von metabotropen glutamatrezeptoren
AU2002360621B2 (en) 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
CN1894241A (zh) * 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
US7074809B2 (en) * 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
TW200812986A (en) 2002-08-09 2008-03-16 Nps Pharma Inc New compounds
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor

Also Published As

Publication number Publication date
CY1110965T1 (el) 2015-06-11
UY28766A1 (es) 2005-08-31
RS51516B (sr) 2011-06-30
ZA200606551B (en) 2007-11-28
IL177394A0 (en) 2006-12-10
CN101096368A (zh) 2008-01-02
WO2006014185A1 (fr) 2006-02-09
ATE483706T1 (de) 2010-10-15
EP1723144A1 (fr) 2006-11-22
CA2555566A1 (fr) 2006-02-09
SI1723144T1 (sl) 2011-01-31
US20080015204A1 (en) 2008-01-17
JP2007523168A (ja) 2007-08-16
NZ548954A (en) 2009-07-31
DK1723144T3 (da) 2011-01-03
PT1723144E (pt) 2010-12-07
HRP20100654T1 (hr) 2011-01-31
US20070293545A1 (en) 2007-12-20
US20080015234A1 (en) 2008-01-17
RU2370495C2 (ru) 2009-10-20
US20050272779A1 (en) 2005-12-08
US20080045571A1 (en) 2008-02-21
US7585881B2 (en) 2009-09-08
AU2005270208A1 (en) 2006-02-09
CN1984907A (zh) 2007-06-20
EP1723144B1 (fr) 2010-10-06
JP4912157B2 (ja) 2012-04-11
ES2352110T3 (es) 2011-02-15
US20070179188A1 (en) 2007-08-02
RU2006128446A (ru) 2008-03-27
NO20063599L (no) 2006-10-27
EP2311830A1 (fr) 2011-04-20
PL1723144T3 (pl) 2011-02-28
UA84318C2 (ru) 2008-10-10
HK1099285A1 (en) 2007-08-10
BRPI0507497A (pt) 2007-07-10
DE602005023963D1 (de) 2010-11-18

Similar Documents

Publication Publication Date Title
SG146657A1 (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
JO2686B1 (en) Vehicles
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
UA87856C2 (ru) Алкильные производные как модуляторы метаботропных рецепторов глутамата
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
MY147767A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
TW200745112A (en) Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
IL181700A0 (en) Quinazoline derivatives and pharmaceutical compositions containing the same
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MY142329A (en) Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2005009387A3 (fr) Derives de l'azepine comme agents pharmaceutiques
MX2007014405A (es) Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
TW200505904A (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
TW200608966A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TW200611695A (en) Pyrrolopyridine derivatives
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007067875A3 (fr) Modulateurs de pyridinylsulfonamide de recepteurs de chimiokine
GB0524814D0 (en) Compounds